目的：探究过继免疫治疗联合BD方案在多发性骨髓瘤治疗中对机体细胞因子水平和Treg细胞水平的影响。方法：选取我院收治的70例多发性骨髓瘤患者，随机分为单纯BD方案治疗组（BD组）和BD方案联合树突状细胞（DC）-细胞因子诱导的杀伤细胞（CIK）治疗组（BD-DC-CIK组）各35例。比较两组治疗有效率、不良反应，血M蛋白、骨髓瘤细胞数、β₂-微球蛋白、血红蛋白表达情况以及血清细胞因子水平和Treg细胞分型含量变化。结果：BD-DC-CIK组治疗总有效率为82.86%，明显高于BD组的54.29%（P<0.05）；BD-DC-CIK组血M蛋白、骨髓瘤细胞数、β₂-微球蛋白指标降低和血红蛋白增高程度均较BD组显著（P<0.05）。治疗后Treg细胞和Th2型细胞因子水平显著下降，Th1型细胞因子水平显著上升，BD-DC-CIK组治疗效果显著优于BD组（P<0.05）。结论：BD方案联合DC-CIK在多发性骨髓瘤的治疗中能够有效改善机体免疫功能，调节免疫失衡，解除Treg诱导的免疫抑制引起的肿瘤免疫逃逸。

[1] 夏祖耀,杨惠娟,陈宝安.多发性骨髓瘤骨病治疗研究进展[J].中国实验血液学杂志,2016,24(1):275-278.
[2] 杨蕊雪,高露,施菊妹.多发性骨髓瘤的诊断进展与分期[J].中国癌症杂志,2014,24(10):727-731.
[3] 赵小强,杨海平,杨学文.沙利度胺结合VAD治疗难治或复发性多发性骨髓瘤的临床疗效研究[J].中国继续医学教育,2016,8(15):167-168.
[4] 秦慧,汪延生,丁士华,等.硼替佐米治疗多发性骨髓瘤的疗效和安全性分析[J].安徽医科大学学报,2014,12(7):1018-1021.
[5] HANDA H,KAMIYA A,NAGAI K,et al.Lenalidomide expand CD3⁺CD56⁺ T cell cytokine induced killer(CIK) cells in vivo in multiple myeloma patients[J].CL Lymph Myelom Leuk,2015,15(10):e296.
[6] 高正兴,童朝晖,张征,等.化疗联合DC-CIK治疗多发性骨髓瘤的疗效及其对VEGF、IL-2及TNF-α的影响[J].湖南师范大学学报:医学版,2015,8(3):47-49.
[7] 左丽宏,杨光忠,王兵,等.联合方案治疗多发性骨髓瘤患者不良反应观察与护理[J].齐鲁护理杂志,2013,19(1):80-82.
[8] ROLLIG C,KNOP S,BORNHAUSER M.Multiple myeloma[J].Lancet,2015,385(9983):2197-2208.
[9] 李增怀.硼替佐米结合地塞米松对多发性骨髓瘤骨病患者生化指标的影响[J].中国生化药物杂志,2015,35(4):138-140.
[10] MURRAY M E,GAVILE C M,NAIR J R,et al.CD28-mediated pro-survival signaling induces chemotherapeutic resistance in multiple mye-loma[J].Blood,2014,123(24):3770-3779.
[11] WANG T F,FIALA M A,CASHEN A F,et al.A phase Ⅱ study of V-BEAM as conditioning regimen before second auto-SCT for multiple myeloma[J].Bone Marrow Transplantation,2014,49(11):1366-1370.
[12] BRYANT S,JR S D,WADDELL J A.Bortezomib,melphalan,and prednisone(VMP) regimen for multiple myeloma[J].Hosp Pharm,2015,50(1):25-30.
[13] FENG P,YAN R,DAI X,et al.The alteration and clinical significance of Th1/Th2/Th17/Treg cells in patients with multiple myeloma[J].Inflammation,2015,38(2):705-709.
[14] RODRIGUEZ T E,PARAMESWARAN H,STIFF P J,et al.Busulfan,melphalan,and bortezomib versus high-dose melphalan as a conditioning regimen for autologous hematopoietic stem cell transplantation in multiple myeloma[J].Biol Blood Marrow Transplant,2016,22(8):1391-1396.
[15] BLANES M,GONZALEZ J D,LAHUERTA J J,et al.Bortezomib-based induction therapy followed by intravenous busulfan-melphalan as conditioning regimen for patients with newly diagnosed multiple myeloma[J].Leuk Lymphoma,2015,56(2):415-419.